Targeting of adenosine receptors in ischemia-reperfusion injury

被引:51
作者
Laubach, Victor E. [1 ]
French, Brent A. [2 ,3 ]
Okusa, Mark D. [3 ]
机构
[1] Univ Virginia Hlth Syst, Dept Surg, Charlottesville, VA 22908 USA
[2] Univ Virginia Hlth Syst, Dept Biomed Engn & Med, Charlottesville, VA 22908 USA
[3] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22908 USA
关键词
inflammation; innate immunity; preconditioning; therapeutic targets; transplantation; ACUTE KIDNEY INJURY; NEUTROPHIL-MEDIATED INJURY; MURINE SEPTIC PERITONITIS; ALVEOLAR EPITHELIAL-CELLS; MYOCARDIAL INFARCT SIZE; MARROW-DERIVED CELLS; NO-REFLOW PHENOMENON; INDUCED LUNG INJURY; PROTEIN-KINASE-C; A(2A) RECEPTOR;
D O I
10.1517/14728222.2011.541441
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Ischemia-reperfusion (IR) injury is a common problem after transplantation as well as myocardial infarction and stroke. IR initiates an inflammatory response leading to rapid tissue damage. Adenosine, produced in response to IR, is generally considered a protective signaling molecule and elicits its physiological responses through four distinct adenosine receptors. The short half-life, lack of specificity and rapid metabolism limits the use of adenosine as a therapeutic agent. Thus, intense research efforts have focused on the synthesis and implementation of specific adenosine receptor agonists and antagonists as potential therapeutic agents for a variety of inflammatory conditions including IR injury. Areas covered in this review: Current knowledge on IR injury with a focus on lung, heart and kidney and studies that have advanced our understanding of the role of adenosine receptors and the therapeutic potential of adenosine receptor agonists and antagonists for the prevention of IR injury. What the reader will gain: Insight into the role of adenosine receptor signaling in IR injury. Take home message: No therapies are currently available that specifically target IR injury; however, targeting of specific adenosine receptors may offer therapeutic strategies in this regard.
引用
收藏
页码:103 / 118
页数:16
相关论文
共 163 条
[1]   Ischaemic and pharmacological preconditionings protect liver via adenosine and redox status following hepatic ischaemia/reperfusion in rats [J].
Ajamieh, Hussam H. ;
Candelario-Jalil, Eduardo ;
Leon Fernandez, Olga Sonia ;
Gerbes, Alexander L. .
CLINICAL SCIENCE, 2008, 115 (1-2) :69-77
[2]   Tissue-derived proinflammatory effect of adenosine A2B receptor in lung ischemia-reperfusion injury [J].
Anvari, Farshad ;
Sharma, Ashish K. ;
Fernandez, Lucas G. ;
Hranjec, Tjasa ;
Ravid, Katya ;
Kron, Irving L. ;
Laubach, Victor E. .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 140 (04) :871-877
[3]   A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs [J].
Auchampach, JA ;
Ge, ZD ;
Wan, TC ;
Moore, J ;
Gross, GJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2003, 285 (02) :H607-H613
[4]   Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges [J].
Auchampach, JA ;
Bolli, R .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 276 (03) :H1113-H1116
[5]   Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury [J].
Awad, Alaa S. ;
Rouse, Michael ;
Huang, Liping ;
Vergis, Amy L. ;
Reutershan, Joerg ;
Cathro, Helen P. ;
Linden, Joel ;
Okusa, Mark D. .
KIDNEY INTERNATIONAL, 2009, 75 (07) :689-698
[6]   INTRACORONARY ADENOSINE ADMINISTRATION DURING REPERFUSION FOLLOWING 3 HOURS OF ISCHEMIA - EFFECTS ON INFARCT SIZE, VENTRICULAR-FUNCTION, AND REGIONAL MYOCARDIAL BLOOD-FLOW [J].
BABBITT, DG ;
VIRMANI, R ;
VILDIBILL, HD ;
NORTON, ED ;
FORMAN, MB .
AMERICAN HEART JOURNAL, 1990, 120 (04) :808-818
[7]   Hepatic ischaemia-reperfusion injury from bench to bedside [J].
Bahde, R. ;
Spiegel, H. -U. .
BRITISH JOURNAL OF SURGERY, 2010, 97 (10) :1461-1475
[8]   Immune Mechanisms and Novel Pharmacological Therapies of Acute Kidney Injury [J].
Bajwa, Amandeep ;
Kinsey, Gilbert R. ;
Okusa, Mark D. .
CURRENT DRUG TARGETS, 2009, 10 (12) :1196-1204
[9]   Adenosine A1 agonist at reperfusion trial (AART):: Results of a three-center, blinded, randomized, controlled experimental infarct study [J].
Baxter, GF ;
Hale, SL ;
Miki, T ;
Kloner, RA ;
Cohen, MV ;
Downey, JM ;
Yellon, DM .
CARDIOVASCULAR DRUGS AND THERAPY, 2000, 14 (06) :607-614
[10]   New concepts in reactive oxygen species and cardiovascular reperfusion physiology [J].
Becker, LB .
CARDIOVASCULAR RESEARCH, 2004, 61 (03) :461-470